Vetoquinol: Availability of the 2022 Universal Registration Document
14 April 2023 - 1:45AM
Business Wire
Regulatory News:
On 13 April 2023, Vetoquinol (Paris:VETO) filed its 2022
Universal Registration Document with the Autorité des Marchés
Financiers (AMF) in ESEF (European Single Electronic Format).
The 2022 Universal Registration Document in ESEF and PDF formats
(reproduction of the official version of the Universal Registration
Document in ESEF format) is available to the public under the
conditions provided by applicable regulations and may be consulted
on the “Investors” page of the Vetoquinol laboratory website
(www.vetoquinol.com), in the “Regulated Information” section. It is
also available on the AMF’s website (www.amf-france.org).
The 2022 Universal Registration Document includes:
- the 2022 Annual Financial Report;
- the Management Report;
- the Board of Directors Report on Corporate Governance;
- the Extra-Financial Performance Declaration;
- the information related to the fees paid to the Statutory
Auditors;
- the share buyback program description; and
- the agenda and draft resolutions of the Shareholder’s Meeting
of May 25th, 2023.
Next update: Shareholder’s Meeting, May 25th, 2023
ABOUT VETOQUINOL Vetoquinol is a leading global animal health
company that supplies drugs and non-medicinal products for the farm
animals (cattle and pigs) and pets (dogs and cats) markets. As an
independent pure player, Vetoquinol designs, develops and sells
veterinary drugs and non-medicinal products in Europe, the Americas
and the Asia Pacific region. Since its foundation in 1933,
Vetoquinol has pursued a strategy combining innovation with
geographical diversification. The Group’s hybrid growth is driven
by the reinforcement of its product portfolio coupled with
acquisitions in high potential growth markets. Vetoquinol employed
2,521 people as of December 31st, 2022. Vetoquinol has been listed
on Euronext Paris since 2006 (symbol: VETO). The Vetoquinol share
is eligible for the French PEA and PEA-PME personal equity
plans.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230413005623/en/
FOR MORE INFORMATION, CONTACT:
VETOQUINOL
Investor Relations Fanny Toillon Tel.: +33 (0)3 84
62 59 88 relations.investisseurs@vetoquinol.com
KEIMA COMMUNICATION
Investor & Media Relations Emmanuel Dovergne
Tel.: +33 (0) 1 56 43 44 63 emmanuel.dovergne@keima.fr
Vetoquinol (EU:VETO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Vetoquinol (EU:VETO)
Historical Stock Chart
From Aug 2023 to Aug 2024